Medexus Pharmaceuticals Inc
F:P731
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Medexus Pharmaceuticals Inc
F:P731
|
CA |
|
Dev Clever Holdings PLC
LSE:DEV
|
UK |
|
Cedar Fair LP
NYSE:FUN
|
US |
|
I
|
Icon Offshore Bhd
KLSE:ICON
|
MY |
|
Mallcom (India) Ltd
NSE:MALLCOM
|
IN |
Wall St Price Targets
P731 Price Targets Summary
Medexus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for P731 is 3.09 EUR with a low forecast of 2.62 EUR and a high forecast of 3.63 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is P731's stock price target?
Price Target
3.09
EUR
According to Wall Street analysts, the average 1-year price target for P731 is 3.09 EUR with a low forecast of 2.62 EUR and a high forecast of 3.63 EUR.
What is the Revenue forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
11%
Over the last 12 years, the compound annual growth rate for Revenue has been 37%. The projected CAGR for the next 4 years is 11%.
What is the Gross Profit forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
18%
The compound annual growth rate for Gross Profit over the next 4 years is 18%.
What is the Operating Income forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
37%
The compound annual growth rate for Operating Income over the next 4 years is 37%.
What is the Pre-Tax Income forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
170%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 170%.
What is the Net Income forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
122%
The compound annual growth rate for Net Income over the next 3 years is 122%.
